Maria Pilar T. L.
- Country
- Spain
- Department
- Rheumatology
Research Overview
- An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.
- Evaluation of Cenerimod Efficacy and Safety in Adults with Moderate-to-Severe Systemic Lupus Erythematosus: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Patients with Active Psoriatic Arthritis: A Phase III Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 120 of 249 partner sites.
Specializations
Autoimmune Disorders
The investigator specializes in the clinical management and research of Sjögren's Disease, exploring innovative therapeutic approaches for this chronic autoimmune condition.
- Systemic Disease Activity Monitoring
- Novel Treatment Evaluation
Their work includes assessment of novel therapeutic agents targeting specific disease mechanisms in Sjögren's Disease.
Rheumatologic Conditions
The investigator focuses on psoriatic arthritis treatment, particularly in patients who have not previously received biologic disease-modifying antirheumatic drugs (DMARDs).
- Early Intervention Strategies
- Biologic DMARD-naive Patient Care
Their research encompasses evaluation of subcutaneous therapeutic options for managing active psoriatic arthritis.
Treatment-Resistant Arthritis
The investigator studies advanced therapeutic options for treatment-resistant psoriatic arthritis, specifically in patients with inadequate response to TNFα inhibitors.
- Alternative Treatment Pathways
- Comparative Treatment Efficacy
Their work includes evaluation of various dosing regimens and comparison with existing therapeutic options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.